Occam Places Ellen Lubman as CBO at Werewolf
Werewolf Therapeutics, an MPM investment, emerged from stealth mode in 2019 with $56M in funding led by serial entrepreneur Dan Hicklin. The company later went public in 2021 tapping the capital markets to finance its pipeline of novel oncology assets.
In August 2020, Occam recruited Ellen Lubman to be CBO. In Lubman, Werewolf captures a richly experienced business development executive with an elevated strategic mind, virtues that will serve the company well as it seeks to deliver on the potential of its robust immunomodulatory platform.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.